Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Sumaya, Alyafei"'
Autor:
Alaa Rahhal, Tahseen Hamamyh, Ammar Chapra, Khaled J. Zaza, Mostafa Najim, Mohammad Hemadneh, Hazem Faraj, Wael Kanjo, Ahmed Yasin, Haneen Toba, Wafa Mohammed, Mohammad Khair Hamad, Nawras Al-Tikrety, Mhd Baraa Habib, Ahmed Awaisu, Ahmed Mahfouz, Sumaya Alyafei, Abdul Rahman Arabi, Ashfaq Patel, Mohammed Al-Hijji
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundAcute coronary syndrome (ACS) remains a risk factor for heart failure (HF). Therefore, we aimed to assess the cardioprotective role of sodium–glucose cotransporter-2 (SGLT2) inhibitors post-ACS in patients with acute HF (AHF) and diabetes
Externí odkaz:
https://doaj.org/article/d5e4e25b24fb49138fcd8c1f0b30226b
Autor:
Marwa Elbashir, Maguy Saffouh ElHajj, Daniel Rainkie, Nadir Kheir, Fatima Hamou, Sara Abdulrhim, Ahmed Mahfouz, Sumaya Alyafei, Ahmed Awaisu
Publikováno v:
Patient Preference and Adherence. 17:89-105
Marwa Elbashir,1,2 Maguy Saffouh ElHajj,1 Daniel Rainkie,1,3 Nadir Kheir,4 Fatima Hamou,5 Sara Abdulrhim,6 Ahmed Mahfouz,5 Sumaya Alyafei,5 Ahmed Awaisu1 1Department of Clinical Pharmacy and Practice, College of Pharmacy, QU Health, Qatar University,
Autor:
Maguy Saffouh El Hajj, Rasha Kaddoura, Safae E. A. Abu Yousef, Bassant Orabi, Ahmed Awaisu, Sumaya AlYafei, Rula Shami, Ziyad R. Mahfoud
Publikováno v:
International Journal of Clinical Pharmacy.
Background Acute coronary syndrome (ACS) is a leading cause of mortality and morbidity in Qatar and globally. Aim The primary objective of the study was to evaluate the effectiveness of a structured clinical pharmacist-delivered intervention on all-c
Autor:
Alaa Rahhal, Mohamed Kasem, Bassant Orabi, Fatima Hamou, Safae Abuyousef, Ahmed Mahfouz, Sumaya Alyafei, Ahmed Emad Shoukry, Emad Ahmed
Publikováno v:
Current problems in cardiology. 48(1)
We conducted a systematic review and meta-analysis to assess all-cause mortality and heart failure (HF) hospitalization with sacubitril/valsartan (S/V) compared to standard HF therapy in patients with HF with reduced ejection fraction (HFrEF) using r
Autor:
Alaa Rahhal, Tahseen Hamamyh, Mostafa Najim, Ammar Farook Chapra, Mohammad Hemadneh, Hazem Faraj, Ahmed Yasin, Haneen A A Toba, Wafa Mohammed, Mohammad Khair Hamad, Mhd Baraa Habib, Ahmed Mahfouz, Sumaya Alyafei, Mohammed Al-Hijji, Abdulrahman Arabi, Ashfaq A.A.H. Patel
Publikováno v:
Journal of the American College of Cardiology. 81:578
Publikováno v:
Journal of the American College of Cardiology. 81:1300
Autor:
Israa Al-Shekh, Abdul Rahman Arabi, Fadi Khir, Ahmed Mahfouz, Alaa Rahhal, Amer Aljundi, Sumaya Alyafei, Masa Habra, Yaser Alahmad, Ahmed Awaisu, Hakam Alzaeem
Publikováno v:
British Journal of Clinical Pharmacology. 87:2043-2052
Aims: To compare the effectiveness and safety of 2 high-intensity atorvastatin doses (40 mg vs 80 mg) among acute coronary syndrome (ACS) patients. Methods: This retrospective observational cohort study using real-world data included patients admitte
Background Sodium glucose co-transporter 2 inhibitors (SGLT2is) are a novel class of oral antidiabetic drugs. To date, there are no pharmacoepidemiologic studies investigating the pattern of use of SGLT2is compared to other oral antidiabetic drugs in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91a59b616dd305e427be6a1c31491f4d
Publikováno v:
Current problems in cardiology. 47(11)
Tachycardia in cardiogenic shock (CS) might reduce the cardiac output (CO) by decreasing the ventricular filling time. Nevertheless, heart rate (HR) control with agents that possess negative inotropy might decrease the CO. Therefore, controlling the
Autor:
Alaa, Rahhal, Fadi, Khir, Bassant, Orabi, Salma, Chbib, Osama, Al-Khalaila, Mohamed Salah, Abdelghani, Omnia, Osman, Amr Azzam, Ashour, Mohammad, Al-Awad, Ahmed, Mahfouz, Ahmed, Awaisu, Amer Hussien, Aljundi, Yaser, Alahmad, Sumaya, Alyafei, Abdul Rahman, Arabi
Publikováno v:
Current problems in cardiology. 47(7)
A high-intensity statin is recommended for the secondary prevention of cardiovascular diseases (CVD). However, real-world evidence of the effectiveness of rosuvastatin following acute coronary syndrome (ACS) is scarce. This retrospective cohort study